No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
RVMD240517C39000
- 1.90
- -1.70-47.22%
15min DelayClose May 8 15:59 ET
1.95High1.80Low
1.80Open3.60Pre Close65 Volume773 Open Interest39.00Strike Price12.27KTurnover92.77%IV6.83%PremiumMay 17, 2024Expiry Date0.00Intrinsic Value100Multiplier8DDays to Expiry1.90Time Value100Contract SizeAmericanOptions Type0.4833Delta0.0718Gamma19.90Leverage Ratio-0.1303Theta0.0040Rho9.62Eff Leverage0.0238Vega
Intraday
- 5D
- 1D
News
Express News | Revolution Medicines Inc : Leerink Partners Raises Target Price to $48 From $37
Revolution Medicines, Inc. (RVMD) Q1 2024 Earnings Call Transcript
Revolution Medicines, Inc. (RVMD) Q1 2024 Earnings Call Transcript
Revolution Medicines Q1 2024 GAAP EPS $(0.70) Beats $(0.75) Estimate
Revolution Medicines (NASDAQ:RVMD) reported quarterly losses of $(0.70) per share which beat the analyst consensus estimate of $(0.75) by 6.67 percent.
Revolution Medicines Q1 Net Loss Narrows
Revolution Medicines (RVMD) reported a Q1 net loss Wednesday of $0.70 per share, narrowing from a loss of $0.72 a year earlier. Analysts polled by Capital IQ expected a loss of $0.75. The company did
Revolution Medicines Reiterates Projected Full Year 2024 GAAP Net Loss To Be $(480)M-$(520)M
Based on the company's current operating plan, the company projects current cash, cash equivalents and marketable securities can fund planned operations into 2027.
Express News | Revolution Medicines Inc: Reiterating Projected 2024 Gaap Net Loss Between $480 Mln and $520 Mln
Comments
$Revolution Medicines(RVMD.US$ rose more than 10% Wednesday after the biotech firm reported the discovery and preclinical-to-clinical translation of its anti-tumor drug RMC-6236.
RVMD gained 10.6% to close at $36.50 on word of the experimental drug, which the company disclosed in the publication Cancer Discovery.
Revolution disclosed news of the drug on Tuesday shortly before the market closed, sending shares up 3.4% that da...
RVMD gained 10.6% to close at $36.50 on word of the experimental drug, which the company disclosed in the publication Cancer Discovery.
Revolution disclosed news of the drug on Tuesday shortly before the market closed, sending shares up 3.4% that da...
1
$Revolution Medicines(RVMD.US$
Someone just sold 25000 shares. How good they are in timing.
Someone just sold 25000 shares. How good they are in timing.
Read more